Abstract | OBJECTIVE: DESIGN AND METHODS: In a 24-week, randomized, double-blind, placebo-controlled, multicenter trial, obese adults with T2DM were randomized (1:1) to weekly subcutaneous taspoglutide 20 mg (10 mg for first 4 weeks) (n = 154) or placebo (n = 151) for 24 weeks. Efficacy measures included hemoglobin A1c (HbA1c) levels, body weight, percentage of patients achieving HbA1c ≤6.5 and ≤7.0%, and fasting plasma glucose (FPG). Adverse events (AEs) were assessed. RESULTS: Mean baseline HbA1c was 7.55% and mean baseline BMI was 36.7 kg/m(2) . HbA1c reductions from baseline were significantly greater with taspoglutide than placebo (least square mean [LSMean], -0.81% vs. -0.09%; P < 0.0001). Weight loss at week 24 was significantly greater with taspoglutide than placebo (LSMean, -3.16 vs. -1.85 kg; P < 0.01). In the taspoglutide and placebo groups, target HbA1c levels (≤6.5%) were achieved by 49 and 16% of patients, respectively, while 72 and 36% achieved HbA1c levels ≤7%. Decreases in FPG were significantly greater with taspoglutide than placebo (-23.59 vs. 0.09 mg/dl; P < 0.0001). Nausea and vomiting were the most common AEs associated with taspoglutide, but tended to be transient and generally mild or moderate. CONCLUSIONS:
|
Authors | Priscilla Hollander, Ben Lasko, Anthony H Barnett, Monica Bengus, Linda Kanitra, F Xavier Pi-Sunyer, Raffaella Balena |
Journal | Obesity (Silver Spring, Md.)
(Obesity (Silver Spring))
Vol. 21
Issue 2
Pg. 238-47
(Feb 2013)
ISSN: 1930-739X [Electronic] United States |
PMID | 23404788
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright © 2012 The Obesity Society. |
Chemical References |
- Anti-Obesity Agents
- Blood Glucose
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Peptides
- taspoglutide
- Metformin
|
Topics |
- Adolescent
- Adult
- Aged
- Anti-Obesity Agents
(therapeutic use)
- Blood Glucose
(analysis)
- Body Mass Index
- Diabetes Mellitus, Type 2
(complications, drug therapy)
- Double-Blind Method
- Fasting
- Female
- Glycated Hemoglobin
(analysis, metabolism)
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Male
- Metformin
(therapeutic use)
- Middle Aged
- Obesity
(complications, drug therapy)
- Peptides
(therapeutic use)
- Weight Loss
(drug effects)
- Young Adult
|